Teva agrees to pay $35 million to settle asthma inhaler antitrust lawsuit
What they're not telling you: Teva's $35 Million Inhaler Settlement: The Price of Monopoly Math Teva Pharmaceutical Industries agreed to pay $35 million to settle an antitrust lawsuit over its dominant grip on the albuterol inhaler market, but the number tells you everything you need to know about why pharmaceutical monopolies survive in America: the fine is the cost of doing business, not the cost of accountability. The settlement resolves claims that Teva, through its subsidiary Anda Inc., engaged in anticompetitive conduct that suppressed generic competition in the albuterol inhaler market—the most widely prescribed rescue inhaler in the United States. The lawsuit alleged that between 2011 and 2016, Teva systematically blocked lower-cost alternatives while maintaining elevated prices on its own products.
What the Documents Show
Patients and healthcare systems paid the difference. Teva paid a settlement that amounts to approximately 0.3 percent of its annual revenue, which hovered around $17 billion in recent years. The company neither admits nor denies wrongdoing. The Federal Trade Commission, which has statutory authority to police anticompetitive conduct in pharmaceutical markets, did not bring this case. Neither did the Department of Justice's Antitrust Division.
Follow the Money
Instead, a class action lawsuit carried the burden—a mechanism that requires individual lawyers to bet their own capital and time on cases the government should be pursuing with publicly funded enforcement. The named plaintiffs in this case represent purchasers of albuterol inhalers who overpaid due to Teva's market manipulation. They received the settlement proceeds; Teva received a pass. What makes this settlement notable is what it reveals about market structure. Albuterol inhalers represent a commodity product with a forty-year history of generic manufacturing. There is no special innovation, no patent protection justifying premium pricing, no scientific advancement being rewarded.
What Else We Know
The inhaler market should be hypercompetitive. Instead, it remained concentrated, with Teva controlling a substantial portion of the market. The $35 million fine, distributed among thousands of individual purchasers, means most Americans who overpaid for a rescue inhaler they needed to breathe will receive checks in the range of $5 to $25. The company's executives and shareholders, by contrast, retained the profits extracted during the anticompetitive period. The settlement required no admission of guilt, no disgorgement of profits beyond the token $35 million payment, and no structural remedies—no forced divestiture, no contractual restrictions on future conduct, no probationary monitoring. Teva continues to operate its inhaler business.
The scandal here is not that Teva paid $35 million. The scandal is that the Federal Trade Commission has essentially abandoned pharmaceutical antitrust enforcement, leaving policing to private lawyers who can only extract settlements, never reform corporate behavior or hold executives accountable.
What I find striking is the structural asymmetry: Teva had every incentive to suppress generic competition in a $2 billion annual market, faced minimal enforcement risk from regulators who lack bandwidth or political will, and calculated that even an unlucky class action settlement would pale against years of anticompetitive profit. The company made the rational choice a monopoly makes when enforcement is weak.
The pattern here is institutional capture disguised as settlement. The FTC's Office of Pharmaceutical Competition has not brought a major unilateral antitrust case against a large pharmaceutical manufacturer since the early 2000s. Lina Khan's FTC has signaled renewed attention to pharma, but settlements negotiated by private counsel do not change market structure or deter executives. They simply redistribute a fraction of ill-gotten gains.
What readers should understand: when the government stops prosecuting, the market doesn't self-correct. Someone pays, but it is not the people who profited. Watch whether the FTC uses its new authority to file cases *before* settlements are negotiated, and demand visibility into how agency leadership allocates resources to pharmaceutical markets where pricing power has already consolidated. That is the measure of whether enforcement is real.
Primary Sources
- Source: Google News (Corporate Watchdog)
- Category: Corporate Watchdog
- Cross-reference independently — don't take our word for it.
Disclosure: NewsAnarchist aggregates from public records, API feeds (Federal Register, CourtListener, MuckRock, Hacker News), and independent media. AI-assisted synthesis. Always verify primary sources linked above.